Protara Therapeutics, Inc. SEC filings TARA
Protara Therapeutics, Inc. has 809 filings in SEC EDGAR's recent list, going back to Apr 14, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 22, 2026 | — |
| CORRESP | Letter to the SEC | May 20, 2026 | — |
| UPLOAD | Letter from the SEC | May 19, 2026 | — |
| EFFECT | Filing | May 9, 2024 | — |
| CORRESP | Letter to the SEC | May 7, 2024 | — |
| UPLOAD | Letter from the SEC | May 7, 2024 | — |
| EFFECT | Filing | Nov 14, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| SEC STAFF LETTER | Filing | Mar 23, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 23, 2021 | — |
| EFFECT | Filing | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2020 | — |
| CORRESP | Letter to the SEC | Dec 15, 2020 | — |
| EFFECT | Filing | May 26, 2020 | — |
| CORRESP | Letter to the SEC | May 21, 2020 | — |
| UPLOAD | Letter from the SEC | May 21, 2020 | — |
| SEC STAFF LETTER | Filing | Mar 2, 2020 | — |
| EFFECT | Filing | Feb 10, 2020 | — |
| CORRESP | Letter to the SEC | Feb 6, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2020 | — |
| SEC STAFF LETTER | Filing | Jan 31, 2020 | — |
| 425 | Form 8-k | Dec 31, 2019 | — |
| RW | Filing | Dec 20, 2019 | — |
| EFFECT | Filing | Dec 19, 2019 | — |
| CORRESP | Letter to the SEC | Dec 18, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Dec 13, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2019 | — |
| CORRESP | Letter to the SEC | Dec 4, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2019 | — |
| 425 | Form 8-k | Nov 21, 2019 | — |
| 425 | 8-k | Sep 24, 2019 | — |
| 425 | 8-k | Sep 24, 2019 | — |
| 425 | 8-k | Sep 23, 2019 | — |
| EFFECT | Filing | Feb 7, 2019 | — |
| CORRESP | Letter to the SEC | Feb 5, 2019 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2019 | — |
| CT ORDER | Filing | Sep 13, 2018 | — |
| EFFECT | Filing | Aug 21, 2017 | — |
| CORRESP | Letter to the SEC | Aug 17, 2017 | — |
| D | Filing | Aug 16, 2017 | — |
| CORRESP | Letter to the SEC | Aug 14, 2017 | — |
| CT ORDER | Filing | Jun 24, 2016 | — |
| EFFECT | Filing | Jan 12, 2016 | — |
| CORRESP | Letter to the SEC | Jan 8, 2016 | — |
| CT ORDER | Filing | Dec 23, 2015 | — |
| CORRESP | Letter to the SEC | Dec 15, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2015 | — |
| CT ORDER | Filing | Oct 22, 2014 | — |
| EFFECT | Filing | Oct 21, 2014 | — |
| CORRESP | Letter to the SEC | Oct 17, 2014 | — |
| CORRESP | Letter to the SEC | Oct 17, 2014 | — |
| 8-A12B | Filing | Oct 16, 2014 | — |
| CERTNAS | Auto-generated paper document | Oct 15, 2014 | — |
| CORRESP | Letter to the SEC | Sep 26, 2014 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2014 | — |
| DRSLTR | Filing | Aug 28, 2014 | — |
| DRSLTR | Filing | Aug 26, 2014 | — |
| DRS/A | Filing | Aug 26, 2014 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2014 | — |
| DRS/A | Filing | Aug 6, 2014 | — |
| DRSLTR | Filing | Aug 5, 2014 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2014 | — |
| DRSLTR | Filing | Jun 25, 2014 | — |
| DRS | Filing | Jun 25, 2014 | — |
| D | Filing | May 28, 2014 | — |
| D | Filing | Feb 19, 2014 | — |
| D | Filing | Aug 11, 2011 | — |
| REGDEX | Auto-generated paper document | Mar 11, 2009 | — |
| REGDEX | Auto-generated paper document | Sep 4, 2007 | — |
| REGDEX/A | Auto-generated paper document | Mar 2, 2007 | — |
| REGDEX/A | Auto-generated paper document | Mar 2, 2007 | — |
| REGDEX | Auto-generated paper document | Apr 14, 2006 | — |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.